↓ Skip to main content

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

Overview of attention for article published in Trials, May 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
Published in
Trials, May 2012
DOI 10.1186/1745-6215-13-61
Pubmed ID
Authors

Corinne SC Merle, Charalambos Sismanidis, Oumou Bah Sow, Martin Gninafon, John Horton, Olivier Lapujade, Mame Bocar Lo, Denis A Mitchinson, Christian Perronne, Francoise Portaels, Joseph Odhiambo, Piero Olliaro, Roxana Rustomjee, Christian Lienhardt, Katherine Fielding

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 1%
Tanzania, United Republic of 1 1%
Vietnam 1 1%
South Africa 1 1%
India 1 1%
United Kingdom 1 1%
Belgium 1 1%
Unknown 68 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 21%
Student > Master 13 17%
Student > Ph. D. Student 10 13%
Student > Postgraduate 5 7%
Student > Bachelor 4 5%
Other 10 13%
Unknown 17 23%
Readers by discipline Count As %
Medicine and Dentistry 29 39%
Agricultural and Biological Sciences 7 9%
Biochemistry, Genetics and Molecular Biology 4 5%
Nursing and Health Professions 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 9 12%
Unknown 18 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2014.
All research outputs
#4,469,464
of 14,579,200 outputs
Outputs from Trials
#1,801
of 3,837 outputs
Outputs of similar age
#96,736
of 265,829 outputs
Outputs of similar age from Trials
#4
of 4 outputs
Altmetric has tracked 14,579,200 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,837 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,829 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.